VSee Health (VSEE)
NASDAQ:VSEE
Want to see VSEE full AI Analyst Report?
Top Page
VSee Health
(NASDAQ:VSEE)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.15
▼(-60.00% Downside)
Action:Upgraded
Date:05/19/26
The score is held down primarily by very weak financial performance (large ongoing losses and negative operating/free cash flow) and a clear bearish technical trend (below major moving averages with negative MACD). Valuation offers limited support due to negative earnings and no dividend, while corporate events provide only a modest offset given dilution risk alongside strategic partnership progress.
Positive Factors
Strategic GoMyRx partnership & equity stake
The multi-year managed services deal (through Dec 26, 2027) with GoMyRx creates a steady, contracted services revenue stream billed at cost plus a 10% margin and aligns incentives via a 10% equity stake. This diversifies revenue, provides predictable cash inflows, and ties VSee to a growing digital-prescription ecosystem, supporting durable commercial expansion and potential cross-selling opportunities.
Negative Factors
Large ongoing cash burn
Sustained negative operating cash flow (~-$5.5M TTM) and similarly negative free cash flow indicate ongoing cash consumption that erodes runway absent financing or rapid margin improvement. This constrains investment in sales, product development, and scaling, increasing reliance on dilutive capital or strategic deals to fund operations over the next 2–6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic GoMyRx partnership & equity stake
The multi-year managed services deal (through Dec 26, 2027) with GoMyRx creates a steady, contracted services revenue stream billed at cost plus a 10% margin and aligns incentives via a 10% equity stake. This diversifies revenue, provides predictable cash inflows, and ties VSee to a growing digital-prescription ecosystem, supporting durable commercial expansion and potential cross-selling opportunities.
Read all positive factors
VSee Health (VSEE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.26M
Dividend YieldN/A
Average Volume (3M)1.90M
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue Growth18.05%
EPS Growth86.68%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.54
Shares Outstanding48,599,422
10 Day Avg. Volume5,577,105
30 Day Avg. Volume1,899,699
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.38
Price to Sales (P/S)0.52
P/FCF Ratio-2.17
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue0.19
Enterprise Value/Gross Profit0.41
Enterprise Value/Ebitda-0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$21.60M
VSee Health Business Overview & Revenue Model
Company Description
VSee Health, Inc. provides telehealth care solutions. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spi...
How the Company Makes Money
VSee Health primarily makes money by providing telehealth software and related services to healthcare organizations on a contractual basis. Key revenue streams include: (1) Software/platform revenue: fees for access to its telehealth platform (typ...
VSee Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
36
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.46M | 14.62M | 10.42M | 5.77M | 6.38M | 7.34M |
| Gross Profit | 6.69M | 7.36M | 7.18M | 3.83M | 4.84M | 5.92M |
| EBITDA | -8.45M | -9.18M | -3.36M | -1.79M | 0.00 | 0.00 |
| Net Income | -13.35M | -14.71M | -57.70M | -3.76M | -836.21K | 475.90K |
Balance Sheet | ||||||
| Total Assets | 19.02M | 22.41M | 19.99M | 805.79K | 2.61M | 117.94M |
| Cash, Cash Equivalents and Short-Term Investments | 1.35M | 5.27M | 326.12K | 118.73K | 230.66K | 760.01K |
| Total Debt | 1.66M | 2.44M | 9.55M | 543.00K | 517.13K | 0.00 |
| Total Liabilities | 12.70M | 16.96M | 20.01M | 5.11M | 2.61M | 4.55M |
| Stockholders Equity | 6.32M | 5.45M | -18.49K | -3.97M | 360.72K | 113.39M |
Cash Flow | ||||||
| Free Cash Flow | -5.50M | -3.48M | -5.84M | -636.93K | -1.45M | -600.11K |
| Operating Cash Flow | -5.46M | -3.45M | -5.79M | -632.60K | -1.45M | -600.11K |
| Investing Cash Flow | -144.81K | -29.93K | -26.14K | -4.33K | 110.12M | -116.73M |
| Financing Cash Flow | 6.54M | 8.42M | 6.02M | 525.00K | -109.32M | 118.09M |
VSee Health Technical Analysis
Negative
0.38
Price Trends
0.22
Negative
0.29
Negative
0.51
Negative
Market Momentum
-0.02
Positive
27.28
Positive
9.84
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEE, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.22, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 27.28 is Positive, neither overbought nor oversold. The STOCH value of 9.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSEE.
VSee Health Risk Analysis
VSee Health disclosed 61 risk factors in its most recent earnings report. VSee Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VSee Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.17B | -3.82 | -12.37% | ― | -1.50% | 83.75% | |
55 Neutral | $131.83M | -2.00 | -35.14% | ― | -9.29% | 46.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $7.26M | -1.15 | 336.68% | ― | 18.05% | 86.68% | |
| ― | $6.09M | -0.58 | -8.26% | ― | -28.30% | -86.73% |
* Healthcare Sector Average
VSEE
VSee Health
0.15
-0.90
-85.81%
TDOC
Teladoc
6.48
-0.49
-7.03%
ZCMD
Zhongchao
1.58
-8.74
-84.69%
AMWL
American Well
7.89
0.45
6.05%
ONMD
OneMedNet
0.87
0.49
127.63%
EUDA
EUDA Health Holdings
18.00
-58.00
-76.32%
VSee Health Corporate Events
Private Placements and FinancingShareholder Meetings
VSee Health Shareholders Approve Major Warrant-Linked Equity Issuance
Positive
Mar 3, 2026
On March 2, 2026, VSee Health, Inc. held a special meeting of stockholders at which 50.46% of the company’s outstanding voting capital stock was represented, satisfying quorum requirements under its amended bylaws. Stockholders considered tw...
Business Operations and StrategyPrivate Placements and Financing
VSee Health Invests in GoMyRx Digital Prescription Platform
Positive
Feb 19, 2026
On December 26, 2025, VSee Health, Inc. and its subsidiary iDoc Virtual Telehealth Solutions, Inc. entered into a Managed Services Agreement with GoMyRx, Inc., a digital prescription fulfillment platform within the GoMyDocs healthcare ecosystem. U...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.